These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 33637328)
1. Candidacy of adult patients with short bowel syndrome for treatment with glucagon-like peptide-2 analogues: A systematic analysis of a single centre cohort. Pironi L; Sasdelli AS; Venerito FM; Musio A; Pazzeschi C; Guidetti M Clin Nutr; 2021 Jun; 40(6):4065-4074. PubMed ID: 33637328 [TBL] [Abstract][Full Text] [Related]
2. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study. Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733 [TBL] [Abstract][Full Text] [Related]
3. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. Jeppesen PB; Gabe SM; Seidner DL; Lee HM; Olivier C Gastroenterology; 2018 Mar; 154(4):874-885. PubMed ID: 29174926 [TBL] [Abstract][Full Text] [Related]
4. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Jeppesen PB; Sanguinetti EL; Buchman A; Howard L; Scolapio JS; Ziegler TR; Gregory J; Tappenden KA; Holst J; Mortensen PB Gut; 2005 Sep; 54(9):1224-31. PubMed ID: 16099790 [TBL] [Abstract][Full Text] [Related]
5. Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome. Lam K; Schwartz L; Batisti J; Iyer KR JPEN J Parenter Enteral Nutr; 2018 Jan; 42(1):225-230. PubMed ID: 29505151 [TBL] [Abstract][Full Text] [Related]
6. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B; O'Keefe SJ Gut; 2011 Jul; 60(7):902-14. PubMed ID: 21317170 [TBL] [Abstract][Full Text] [Related]
7. Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome. Yazbeck R Curr Opin Mol Ther; 2010 Dec; 12(6):798-809. PubMed ID: 21154171 [TBL] [Abstract][Full Text] [Related]
8. Experience with teduglutide treatment for short bowel syndrome in clinical practice. Pevny S; Maasberg S; Rieger A; Karber M; Blüthner E; Knappe-Drzikova B; Thurmann D; Büttner J; Weylandt KH; Wiedenmann B; Müller VA; Bläker H; Pascher A; Pape UF Clin Nutr; 2019 Aug; 38(4):1745-1755. PubMed ID: 30145039 [TBL] [Abstract][Full Text] [Related]
9. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Jeppesen PB; Pertkiewicz M; Messing B; Iyer K; Seidner DL; O'keefe SJ; Forbes A; Heinze H; Joelsson B Gastroenterology; 2012 Dec; 143(6):1473-1481.e3. PubMed ID: 22982184 [TBL] [Abstract][Full Text] [Related]
10. Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure. Chen K; Mu F; Xie J; Kelkar SS; Olivier C; Signorovitch J; Jeppesen PB JPEN J Parenter Enteral Nutr; 2020 Jan; 44(1):119-128. PubMed ID: 31006876 [TBL] [Abstract][Full Text] [Related]
11. Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study. Joly F; Seguy D; Nuzzo A; Chambrier C; Beau P; Poullenot F; Thibault R; Armengol Debeir L; Layec S; Boehm V; Lallemand J; Quilliot D; Schneider SM Clin Nutr; 2020 Sep; 39(9):2856-2862. PubMed ID: 31932048 [TBL] [Abstract][Full Text] [Related]
12. Long-term results of teduglutide treatment for chronic intestinal failure - Insights from a national, multi-centric patient home-care service program. Greif S; Maasberg S; Wehkamp J; Fusco S; Zopf Y; Herrmann HJ; Lamprecht G; Jacob T; Schiefke I; von Websky MW; Büttner J; Blüthner E; Tacke F; Pape UF Clin Nutr ESPEN; 2022 Oct; 51():222-230. PubMed ID: 36184208 [TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure. Kochar B; Long MD; Shelton E; Young L; Farraye FA; Yajnik V; Herfarth H J Clin Gastroenterol; 2017 Jul; 51(6):508-511. PubMed ID: 27433811 [TBL] [Abstract][Full Text] [Related]
15. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome. Thymann T; Stoll B; Mecklenburg L; Burrin DG; Vegge A; Qvist N; Eriksen T; Jeppesen PB; Sangild PT J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):694-702. PubMed ID: 24399211 [TBL] [Abstract][Full Text] [Related]
16. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome. Tappenden KA; Edelman J; Joelsson B J Clin Gastroenterol; 2013 Aug; 47(7):602-7. PubMed ID: 23426461 [TBL] [Abstract][Full Text] [Related]